Trial
NCT00310232
Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20)
Phase IIITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Ontario Clinical Oncology Group (OCOG)
Collaborators
Ortho Biotech, Inc.
Condition
Non-Small-Cell Lung Carcinoma
Intervention
Epoetin Alfa
Why stopped
Recommendation of DSMB for safety issue, increased mortality with study drug.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-04-02